Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Rhythm Pharmaceuticals	Arcturus Therapeutics	Trillium Therapeutics	Constellation Pharmaceuticals	MannKind
Symbol	NASDAQ:RYTM	NASDAQ:ARCT	NASDAQ:TRIL	NASDAQ:CNST	NASDAQ:MNKD
Price Information
Current Price	$22.12	$31.80	$9.59	$20.80	$4.29
52 Week Range	Buy	Hold	Buy	Buy	Buy
MarketRank™
Overall Score	1.8	1.6	1.7	1.2	1.4
Analysis Score	3.4	3.1	3.5	3.4	3.5
Community Score	2.6	2.6	2.9	2.4	2.2
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	2.5	1.7	1.7	0.0	0.8
Earnings & Valuation Score	0.6	0.6	0.6	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Hold	Buy	Buy	Buy
Consensus Price Target	$50.67	$70.67	$21.83	$40.33	$6.63
% Upside from Price Target	129.05% upside	122.22% upside	127.67% upside	93.91% upside	54.43% upside
Trade Information
Market Cap	$1.11 billion	$836.98 million	$988.09 million	$996.61 million	$1.07 billion
Beta	1.57	3.01	2.27	2.8	2.28
Average Volume	447,557	1,084,261	1,441,325	462,367	5,380,282
Sales & Book Value
Annual Revenue	N/A	$20.79 million	$120,000.00	N/A	$63.04 million
Price / Sales	N/A	40.26	8,234.05	N/A	16.95
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$6.40 per share	$1.70 per share	($0.86) per share	$8.23 per share	($0.92) per share
Price / Book	N/A	18.71	-11.15	N/A	-4.66
Profitability
Net Income	$-140,730,000.00	$-25,990,000.00	$-41,620,000.00	$-85,550,000.00	$-51,900,000.00
EPS	($3.86)	($2.15)	($1.38)	($3.04)	($0.27)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	-506.70%	N/A	N/A	-71.92%
Return on Equity (ROE)	-55.21%	-52.32%	-70.00%	-28.88%	N/A
Return on Assets (ROA)	-50.73%	-33.21%	-28.84%	-24.98%	-46.80%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.06%	N/A	0.05%	N/A
Current Ratio	13.24%	11.21%	22.44%	15.81%	0.63%
Quick Ratio	13.25%	11.21%	22.44%	15.81%	0.58%
Ownership Information
Institutional Ownership Percentage	88.43%	74.33%	67.46%	N/A	29.60%
Insider Ownership Percentage	9.49%	12.60%	N/A	10.60%	1.09%
Miscellaneous
Employees	90	118	N/A	154	240
Shares Outstanding	50.21 million	26.32 million	103.03 million	47.91 million	249.07 million
Next Earnings Date	8/2/2021 (Estimated)	5/10/2021 (Confirmed)	8/11/2021 (Estimated)	5/10/2021 (Confirmed)	5/12/2021 (Confirmed)
Optionable	Optionable	Optionable	Optionable	Not Optionable	Optionable

Source	Headline
	MannKind Stock Is Believed To Be Significantly Overvalued gurufocus.com - May 9 at 12:43 AM
	Analysts Say MannKind Corporation (NASDAQ:MNKD) Can Really Get to $8 in 12 Months marketingsentinel.com - May 8 at 7:38 AM
	MannKind (MNKD) Scheduled to Post Quarterly Earnings on Wednesday americanbankingnews.com - May 6 at 12:59 PM
	MannKind Co. (NASDAQ:MNKD) Forecasted to Post FY2022 Earnings of ($0.15) Per Share americanbankingnews.com - May 6 at 11:12 AM
	MannKind (NASDAQ:MNKD) Cut to Strong Sell at Zacks Investment Research marketbeat.com - May 6 at 2:18 AM
	MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021 - Yahoo Finance finance.yahoo.com - May 5 at 1:17 PM
	MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021 finance.yahoo.com - May 5 at 1:17 PM
	Marshall & Sullivan Inc Buys iShares Russell 2000 ETF, Vanguard FTSE Emerging Markets ETF - GuruFocus.com gurufocus.com - May 5 at 8:16 AM
	MannKind Corporation (MNKD) investors to reap big returns again marketingsentinel.com - May 4 at 9:59 AM
	Take A Look At This MannKind Corporation (NASDAQ:MNKD) Analysis Before You Invest stocksregister.com - May 3 at 1:48 PM
	Inhalers Market: Know about Impact of Covid-19 by Top Companies like – Orion Pharm, MannKind, Hovione, Merck, Aristopharma, Novartis, and more – Clark County Blog - Clark County Blog clarkcountyblog.com - May 1 at 1:51 PM
	Global Diabetes Drug Therapy Market 2021 Regional Outlook – Abbott Laboratories, Mannkind Corporation, Bristol Myers Squibb, Medtronic – Jumbo News - Jumbo News jumbonews.co.uk - May 1 at 8:50 AM
	Huge Demand of Anaphylaxis Market by 2026 \| Impax Laboratories Inc., MannKind Corporation, ALK-Abelló, Lincoln Medical Ltd., Adamis Pharmaceutical Corporation - Clark County Blog clarkcountyblog.com - April 30 at 7:25 PM
	Medical Inhaler Market 2021 In-depth Analysis, Growth with Forecast 2025 : GSK, Novartis, AstraZeneca, Chiesi, Cipla, Boehringer Ingelheim, Mannkind, 3M, Mylan, Hovione, ResMed - Clark County Blog clarkcountyblog.com - April 29 at 1:37 PM
	Earnings Preview: MannKind (MNKD) Q1 Earnings Expected to Decline - Yahoo Finance finance.yahoo.com - April 28 at 2:46 PM
	Earnings Preview: MannKind (MNKD) Q1 Earnings Expected to Decline finance.yahoo.com - April 28 at 2:46 PM
	Receptor Life Sciences Announces Poster Presentations at the Respiratory Drug Delivery 2021 Conference - StreetInsider.com streetinsider.com - April 27 at 8:48 AM
	MannKind Reduces Debt by Nearly $50 Million - San Fernando Valley Business Journal sfvbj.com - April 26 at 7:21 PM
	Antares Pharma Appoints Dr. Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer - StreetInsider.com streetinsider.com - April 26 at 9:19 AM
	MannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche - GlobeNewswire globenewswire.com - April 26 at 9:19 AM
	MannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche finance.yahoo.com - April 26 at 9:19 AM
	Global Diabetes Mellitus Treatment Market Top Manufacturers Analysis by 2026: Novo Nordisk, Sanofi, MannKind, Bristol-Myers Squibb, AstraZeneca etc. – Clark County Blog - Clark County Blog clarkcountyblog.com - April 25 at 1:16 PM
	MNKD June 4th Options Begin Trading - Nasdaq nasdaq.com - April 23 at 3:48 AM
	MannKind (NASDAQ:MNKD) Stock Price Down 4.1% americanbankingnews.com - April 22 at 12:50 PM
	Unlocking Growth Opportunity in MannKind Corporation (NASDAQ:MNKD) stocksregister.com - April 22 at 12:22 PM
	Market Analysts see MannKind Corporation [MNKD] gaining to $2.50. Time to buy? dbtnews.com - April 22 at 12:22 PM

Date	Company	Brokerage	Action
3/9/2021	Rhythm Pharmaceuticals	Morgan Stanley	Boost Price Target
1/27/2021	Rhythm Pharmaceuticals	Stifel Nicolaus	Boost Price Target
1/27/2021	Rhythm Pharmaceuticals	Canaccord Genuity	Boost Price Target
1/27/2021	Rhythm Pharmaceuticals	LADENBURG THALM/SH SH	Boost Price Target
11/30/2020	Rhythm Pharmaceuticals	Bank of America	Downgrade
8/3/2020	Rhythm Pharmaceuticals	Needham & Company LLC	Initiated Coverage
1/8/2020	Rhythm Pharmaceuticals	The Goldman Sachs Group	Initiated Coverage
9/25/2019	Rhythm Pharmaceuticals	Cowen	Reiterated Rating
3/8/2021	Arcturus Therapeutics	B. Riley	Lower Price Target
3/2/2021	Arcturus Therapeutics	Roth Capital	Lower Price Target
1/7/2021	Arcturus Therapeutics	Wells Fargo & Company	Initiated Coverage
12/29/2020	Arcturus Therapeutics	HC Wainwright	Downgrade
12/29/2020	Arcturus Therapeutics	Robert W. Baird	Downgrade
12/29/2020	Arcturus Therapeutics	Barclays	Downgrade
12/29/2020	Arcturus Therapeutics	Raymond James	Downgrade
12/14/2020	Arcturus Therapeutics	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target
12/14/2020	Arcturus Therapeutics	Smith Barney Citigroup	Boost Price Target
8/25/2020	Arcturus Therapeutics	Piper Sandler	Initiated Coverage
8/11/2020	Arcturus Therapeutics	Brookline Capital Management	Reiterated Rating
4/29/2021	Trillium Therapeutics	Bloom Burton	Upgrade
4/26/2021	Trillium Therapeutics	Jonestrading	Reiterated Rating
4/20/2021	Trillium Therapeutics	Benchmark	Initiated Coverage
11/18/2020	Trillium Therapeutics	Craig Hallum	Boost Price Target
10/12/2020	Trillium Therapeutics	Evercore ISI	Initiated Coverage
9/9/2020	Trillium Therapeutics	JMP Securities	Boost Price Target
4/7/2021	Constellation Pharmaceuticals	Royal Bank of Canada	Reiterated Rating
1/25/2021	Constellation Pharmaceuticals	BMO Capital Markets	Upgrade
9/24/2020	Constellation Pharmaceuticals	Oppenheimer	Reiterated Rating
8/9/2020	Constellation Pharmaceuticals	Jefferies Financial Group	Reiterated Rating
2/13/2020	Constellation Pharmaceuticals	SunTrust Banks	Initiated Coverage
3/11/2021	MannKind	SVB Leerink	Boost Price Target
2/24/2021	MannKind	BTIG Research	Boost Price Target
11/5/2020	MannKind	Cantor Fitzgerald	Reiterated Rating
6/15/2018	MannKind	Maxim Group	Reiterated Rating

(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources